Floatz logo

(8S)-8-ETHYL-2,3-DIHYDRO-8-HYDROXY-15-((4-METHYL-1-PIPERAZINYL)METHYL)-11H-P-DIOXINO(2,3-G)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-9,12(8H,14H)-DIONE

Unspecified Adult Solid Tumor, Protocol Specific

NCIC Clinical Trials GroupSmall moleculePhase 1Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Unspecified Adult Solid Tumor, Protocol Specific cohort.

Asset / SponsorPhaseRating
NEPENTHE
M.D. Anderson Cancer Center
Phase 4BBB
Amifostine
M.D. Anderson Cancer Center
Phase 4BBB
DEXAMETHASONE
Alliance for Clinical Trials in Oncology
Phase 3BBB
ETOPOSIDE
University of California, Davis
Phase 2/3BBB
Evomela
City of Hope Medical Center
Phase 2/3BBB

View all 50 →

Same molecule, other indications

(8S)-8-ETHYL-2,3-DIHYDRO-8-HYDROXY-15-((4-METHYL-1-PIPERAZINYL)METHYL)-11H-P-DIOXINO(2,3-G)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-9,12(8H,14H)-DIONE is also rated in:

primary peritoneal carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Carcinoma, Small CellDormant
B
Indicative ·
57 / 100
View asset →
small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →